Our Pipeline
Character Bio is translating its understanding of human disease into a clinical-stage pipeline and discovery research aimed at addressing important unmet needs in ophthalmology.
Our two clinical programs address different stages of dry age-related macular degeneration (AMD): high-risk intermediate AMD and geographic atrophy. Both programs originated from insights generated through Character Arc™, our disease intelligence system. We are also applying this approach to discovery research in primary open-angle glaucoma (POAG).
CTX114
Geographic Atrophy
Phase 1
CTX114 is a potential best-in-class complement inhibitor being developed for geographic atrophy, the advanced form of dry AMD. Existing therapies can slow disease progression, but significant unmet need remains for treatments that can preserve retinal structure and visual function with less treatment burden and improved safety.
CTX114 builds on the validated role of the complement system in geographic atrophy and is designed to prevent complement attack at the retinal surface, where disease-related damage occurs, with the goal of protecting retinal and photoreceptor cells essential to maintaining vision.
CTX203
High risk intermediate AMD
PHASE 1
CTX203 is a potential first-in-class lipid-modulating therapy being developed for high-risk intermediate dry AMD, a stage of disease with no approved medicines. It is designed to intervene earlier in the course of disease, before irreversible retinal damage occurs, when there may be the greatest opportunity to preserve vision.
Insights from Character Arc™ helped identify lipid dysregulation as an important pathogenic driver and prognostic indicator of disease progression. CTX203 is designed to restore lipid homeostasis to prevent progression to advanced disease.
AMD
Undisclosed
RESEARCH
POAG
Undisclosed
RESEARCH